Orchard Therapeutics

Orchard Therapeutics

Orchard Therapeutics is a biotechnology company developing gene therapies for rare diseases.

Orchard Therapeutics is a biotechnology company developing gene therapies for patients with rare diseases. The company has a portfolio of approved ex vivo gene therapies.

Timeline

February 5, 2021
Orchard Therapeutics raises a $150,000,000 venture round from Avidity Partners, Surveyor Capital, RA Capital Management, Farallon Capital Management and Casdin Capital.
August 2018
Orchard Therapeutics raises a $150,000,000 series C round from Deerfield Capital Management, RTW Investments LLC, Medison Ventures, Venrock, Temasek Holdings, Foresite Capital, Perceptive Advisors and Driehaus Capital Management.
December 20, 2017
Orchard Therapeutics raises a $110,000,000 series B round from RTW Investments LLC, Pavilion Capital, Baillie Gifford, Temasek Holdings, Cowen Group, F-Prime, UCL Technology Fund and Agent Capital.
November 23, 2016
Orchard Therapeutics raises a $20,000,000 grant from California Institute for Regenerative Medicine.
May 3, 2016
Orchard Therapeutics raises a $29,660,000 series A round from AlbionVC and UCL Technology Fund.
2015
Orchard Therapeutics was founded by Bobby Gaspar.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Orchard Therapeutics Series B round, December 20, 2017
110,000,000
December 20, 2017
5 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California

Orchard Therapeutics

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
AGC Biologics
January 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- AGC Biologics, destacada organización farmacéutica líder en desarrollo de contratos y fabricación (CDMO), es el primer fabricante del producto...
BioSpace
November 19, 2020
BioSpace
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of metachromatic leukodystrophy (MLD). The company also has applied for Regenerative Medicine Advanced Therapy (RMAT) des
Krystle Vermes
June 9, 2020
BioSpace
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
Amirah Al Idrus
June 9, 2020
FierceBiotech
In 2019, it was all systems go for Orchard Therapeutics. The company had pulled off a $200 million IPO, picked up GlaxoSmithKline's stable of rare disease gene therapies and planned to break ground on a $90 million manufacturing site in California. Now, under the wing of a new CEO, the company has reined it in.
Ben Adams
May 8, 2020
FierceBiotech
Tough times at Orchard Therapeutics as it swings the ax across staffers and facilities, phases in new pipeline advances and reduces interest in others.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.